Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-12-15
1996-04-16
Warden, Jill
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 530324, 530351, A61K 3800, C07K 710
Patent
active
055082629
ABSTRACT:
A method for treating acute pancreatitis comprising administering an effective amount of Interleukin-1 receptor antagonist (IL-1ra) or a pharmaceutically acceptable salt thereof to a person afflicted with that condition.
REFERENCES:
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4475196 (1984-10-01), LaZor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4522827 (1985-06-01), Marlettini et al.
patent: 4902708 (1990-02-01), Kim
patent: 4975464 (1990-12-01), Imaki et al.
patent: 5196402 (1993-03-01), Braganza et al.
patent: 5220018 (1993-06-01), Bock et al.
Grewal, et al, Surgery, Feb., 1994, pp. 213-221.
Grewal, et al, Am. J. Surg. 167(1), 214-20, 1994.
Guice, et al J. Surg. Res, 51(6) 495-9. 1991.
Leach et al., 1992, "New Perspectives on Acute Pancreatitis", Scan. J. Gastroenterol 27 Suppl. 192:29-38.
Murayama et al., 1990, "Does Somatostatin Analogue Prevent Exper. Acute Pancreatitis?" Arch. Surg. 125:1570-1572 (Dec.).
Zhu et al., 1991, "Somatostatin analogue is protective against retrograde bile salt-induced pancreatitis in rat", Pancreas 6:609-613.
Spillenaar et al., 1989, "Attempts to reduce post-transplant pancr. in rats and dogs with somatostatin analogue SMS 201-995," Transplant Proceed 21:2829-2830.
Dinarello et al., 1993, "Anticytokine Strategies in Treatment of Systemic Inflammatory Response Syndrome", JAMA 269(14):1829-1834.
Steer, 1992, "How and where does acute pancreatis begin?" Arch. Surg 127:1350-1353.
Tani et al., 1987, "Histologic and biochemical alterations in experimental acute pancreatis induced by supramaximal caerulein stimulation", Int. J. Pancretology. 2:337-348.
Van Ooijen et al., 1990, "Significance of thromboxane A.sub.2 and Prostaglandin I.sub.2 in acute necrotizing pancreatitis in rats", Digestive Dis. and Sciences, 35:1078-1084.
Schoenberg et al., 1992, "The role of oxygen radicals in experimental acute pancreatitis", Free Radical Biology & Medicine, 12:515-522.
Kelly et al., 1993, "Microvasculature of the pancreas, liver, and kidney in caerulein-induced pancreatitis", Arch Sug, 128:293-295.
Guice et al., 1991, "Anti-tumor Necrosis Factor Antibody Augments Edema Formation in Caerulein-Induced Acute Pancreatitis", 51:495-499.
Heath et al., 1993, "Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis", Pancreas 66:45-45.
Larsen and Henson, 1983, "Mediators of Inflammation", Immunol. 1:335-359.
Deitch, 1992, "Multiple Organ Failure", Ann. Surg. 216:117-134.
Michie and Wilmore, 1990, "Sepsis, Signals, and Surgical Sequelae (A Hypothesis)", Arch. Surg. 125:531-536.
Ellison et al., 1981, "Demonstration and Characterization of Hemoconcentrating Effect of Ascitic Fluid That Accumulates . . . " J. Surg. Research 30:241-248.
Wakabayashi et al., 1991, "A specific receptor antagonist for interleukin 1 prevents E. coli-induced shock in rabbits", FASEB J. 5:338-343.
Okusawa et al., 1988, "Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition", J. Clin. Invest. 81:1162.
Ohlsson et al., 1990, "Interleukin-1 receptor antagonist reduced mortality from endotoxin shock", Nature 348:550-551.
Aiura et al., 1991, "Interleukn-1 receptor antagonist blocks hypotension in rabbit model of gram-positive septic shock", Cytokine 4:498.
Fischer et al., 1991, "A comparison between effects of interleukin-1.alpha. administration and sublethal endotoxemia in primates", Am. J. Physiol. 261:R444.
Waage and Espevik, 1988, "Interleukin-1 potentiates the lethal effect of tumor necrosis factor/cachectin in mice", J. Exp. Med. 1678:1987.
Fischer et al., "Interleukn-1 Receptor Blockade Improves Survival and Hemodynamic Performance in E. coli Septic Shock . . . ", J. Clin. Invest. 89:1551-1557.
Granowitz et al., 1992, "Pharmacokinetics, Safety, Immunomodulatory Effects of Human Recombinant Interluekin-1 Receptor Antagonist in Healthy Humans", Cytokine 4(5):353-360.
Bloedow et al., 1992, "Intravenous Disposition of Interleukin-1 Receptor Antagonist in Healthy Volunteers", Amer. Soc. Clin. Pharm. and Therapeutics, Orlando, Florida (Abstract).
Investigator's Handbook, Cancer Therapy Evaluation Program, National Cancer Institute, pp. 22-23--no date on ref.
Driscoll, 1984, "The Preclinical New Drug Research Program of Nat. Cancer Institute", Cancer Treatment Reports 68:63-76.
Saluja et al., 1985, "In Vivo rat pancreatic acinar cell function during supramaximal stimulation with caerulein." Amer. Physiol. Soc. pp. G702-G710.
Manso et al., 1992, "Cerulein-Induced Acute Pancreatitis in the Rat", Digestive Diseases and Sciences, 37:364-368.
Protocol No. 0556, 1993, "Study to Evaluate Safety and Efficacy of Human Recombinant Interleukin-1 Receptor Antagonist (IL-1ra) . . . ", A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
Opal et al., 32nd ICAAC, Oct. 1992, "Phase II Interleukin-1 Receptor Antagonist Sepsis Syndrome Trial: Analysis of Clin., Cytokine and Microbial Features with Outcome" (Abstract).
Fisher et al., Oct. 1991, American College of Chest Physicians, "Interleukin-1 Receptor Antagonist (IL-1ra) Reduced Mortality in Patients with Sepsis Syndrome" (Abstract).
Grewal et al., Feb. 1994, "Induction of tumor necrosis factor in severe acute pancreatitis and its subsequent reduction after hepatic passage", Surgery 115(2):213-221.
Grewal et al., Jan. 1994, "Amelioration of Physiologic and Biochemical Changes of Acute Pancreatitis Using an Anti-TNF-.alpha. Polyclonal Antibody" Amer. J. Surg. 167:214-219.
Dower et al., 26th Annual Scientific Mtg., European Soc. for Clinical Investigation, Apr. 1-4, 1992, Vienna, Austria.
Fisher et al., 1994, "Initial evaluation of human recombinant IL-1 receptor antagonist in treatment of sepsis syndrome . . . ", Critical Care Medicine 22(1):12-21.
Gjorup et al., 1992, "Double-Blinded Multicenter Trial of Somatostatin in Treatment of Acute Pancreatitis", Surgery, Gyn & Ob. 175:397-.
Fisher et al., 1993, "Study Evaluating Efficacy of Human Recombinant Interleukin-1 Receptor Antanist Treatment of Patients with Sepsis Syndrome . . . " Clin. Intensive Care 4:8S.
Dinarello and Wolff, Jan. 1993, "The role of interleukin-1 in disease", New England J. Med., 328(2)106-113.
Innes et al., 1986, "The Vasoactive Properties of Ascitic Fluid in Acute Pancreatitis in Porcine Model", Arch. Surg. 121:665 (Jun.).
Marshall S. G.
University of South Florida
Warden Jill
LandOfFree
Interleukin-1 receptor antagonist decreases severity of acute pa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-1 receptor antagonist decreases severity of acute pa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-1 receptor antagonist decreases severity of acute pa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-325174